APRE Aprea Therapeutics, Inc. Insider Trading

APRE CEO Gilad Oren buys 28,100 shares at $0.89; stock now $0.75, down 81.5% from 52-week high of $4.06

CEO Gilad Oren acquired 28,100 shares at $0.89 on 2026-01-30, expanding his holdings to 373,720 shares (+8.1%). The stock has declined sharply: currently $0.75 (down 81.5% from the 52-week high of $4.06), with a 30-day loss of -12.1% and 90-day loss of -45.3%. Against his cross-ticker track record of 7 prior buys averaging +5.2% over 30 days and +9.2% over 90 days (57.14% win rate), his prior five purchases at APRE show mixed results, with only 3 of 5 well-timed at the 90-day mark. Notably, Aprea Therapeutics remains unprofitable with net income of $-2,972,410.00 on a market cap of $4,733,004.75, suggesting the purchase occurred into a deeply distressed financial backdrop.

CFO Hamill bought 5,700 APRE shares at $0.89 on 2026-01-30; stock now at $0.75, -81.5% from $4.06 high.

Hamill (SrVP/CFO/Prin Fin & Acct Ofcr) purchased 5,700 shares at $0.89, increasing his holdings by 20.6% to 33,433 shares post-transaction. The stock has declined 12.1% in the 30 days since this buy and is down 45.3% over 90 days, now trading at $0.75 versus a 52-week high of $4.06. While Hamill's cross-ticker track record shows an average 90-day return of +24.0% with a 66.67% win rate, his prior four trades at APRE specifically show mixed timing: two produced substantial gains (2024-10-10 and 2024-10-11 both exceeded +36% at the 30-day mark and +51% at 90 days), but another buy on 2025-12-10 was -18.9% at 30 days, and an earlier March 2024 buy was -38.8% at 90 days. The company posted a net loss of $-2,972,410.00 in its most recent full fiscal year, with a market cap of $4,733,004.75, placing this microcap in a deteriorating financial and valuation context. The timing and rationale of this purchase, given the steep stock decline post-transaction and the company's unprofitable state, merit monitoring.

Director Marc Duey bought 21.5K shares of APRE at $1.16; stock now $0.94, down 78.1% from 52-week high, company unprofitable.

Marc Duey, a Director, purchased 21,459 shares at $1.16 on 2025-12-10, increasing his holdings to 256,155 shares (+9.1%). The purchase occurs in a severely depressed price environment: APRE trades at $0.94, down -78.1% from its 52-week high of $4.30 and -28.8% over the past 30 days. The company reported net income of $-2,972,410.00 ($-3.0M) over its most recent full fiscal year and maintains a market cap of only $5,932,032.62 ($5.9M). Looking at his prior trades at APRE, his timing has been mixed—his October 2024 purchases show a 90-day split of -17.5% and +41.7%, with only 1 of 2 prior buys well-timed at the 90-day mark. His broader open-market track record across all tickers is modest (2 prior buys averaging +1.0% over 30 days and +12.1% over 90 days, with a 50% win rate), providing limited predictive confidence for this transaction. The buy in a micro-cap, unprofitable company trading near 52-week lows, combined with mixed prior outcomes at this ticker, reflects a high-risk transaction without clear conviction signals.

CFO John P. Hamill buys 5,000 APRE shares at $1.16; stock down 78.1% from 52-week high, unprofitable company (net income $-3.0M).

John P. Hamill, SrVP/CFO, purchased 5,000 shares of Aprea Therapeutics at $1.16 on 2025-12-10, increasing his holdings by 22.0% to 27,733 shares post-transaction. The transaction occurs in a severely distressed context: the stock trades at $0.94 (down 78.1% from its 52-week high of $4.30), has declined 28.8% over the prior 30 days and 39.1% over 90 days, and the company reported full-year net income of $-3.0M with a market cap of $5.9M. At this ticker specifically, Hamill's prior two most recent buys (October 2024) were well-timed at the 90-day mark, with returns of 44.1% and 36.0% respectively; however, an earlier March 2024 buy at APRE resulted in a 90-day loss of 38.8%, demonstrating mixed performance on this specific name. The current purchase at depressed levels and significant portfolio concentration increase—adding a 22% stake in a microcap unprofitable business—presents a material open-market capital commitment by a financial officer in the face of negative momentum and negative fundamentals.

CEO Gilad Oren bought 5,500 shares at $1.84 avg; stock now $1.70 (-74.5% from 52-week high, -35.6% in 30d)

Gilad Oren, President and CEO of Aprea Therapeutics, executed 2 separate purchases totaling 5,500 shares for $10,110.21 at a blended average price of $1.84 on 2025-04-03, increasing his holdings by 1.6% to 345,620 shares. The stock has fallen to $1.70, trading 74.5% below its 52-week high and down 35.6% over 30 days—reflecting severe recent deterioration. His prior timing at APRE shows mixed execution: 4 of 5 prior buys at this ticker achieved positive 90-day returns, though the most recent October 2024 purchase returned -26.4% over 30 days before recovering. The company remains unprofitable with a net loss of $3,783,769.00 and market cap of $9,336,320.10, so the fundamental backdrop is challenged. The CEO's continued accumulation into a sharply declining stock while the company is burning cash warrants scrutiny of his assessment of intrinsic value relative to market pricing.

APRE CEO buys 500 shares at $3.92; stock down 53.9% from 52-week high, part of cluster of 4 insider buys in 14 days.

Gilad Oren, the company's President and CEO, purchased 500 shares of Aprea Therapeutics at $3.92 on 2024-10-23, bringing his holdings to 333,395 shares. This transaction occurred alongside 3 other insider purchases within the past 14 days, forming a cluster-buy pattern. However, the company remains unprofitable with a net income of $-3,470,052.00 over its most recent full fiscal year, and the stock trades at $3.90 currently—down 53.9% from its 52-week high of $8.46. Oren's cross-ticker track record shows poor outcomes: prior open-market buys averaged -21.7% return over 30 days and -38.8% over 90 days with a 0.00% win rate, though his same-ticker history at APRE includes a March 2024 purchase that declined 38.8% over 90 days. The cluster activity and CEO participation warrant attention to whether additional operational or strategic context exists, but the magnitude ($1,957.50 total value) and Oren's historical timing pattern merit careful scrutiny.

Director Duey Marc buys 30,000 APRE shares at $4.39; 3 other insiders also bought within 14 days.

Director Duey Marc purchased 30,000 shares at $4.39 on 2024-10-16, increasing his holdings by 14.3% to 240,113 shares. This buy appears as part of a broader cluster pattern: 3 other insiders also purchased shares within the past 14 days. The stock trades at $4.45 currently, down 47.4% from its 52-week high of $8.46 but up 47.8% over the past 30 days. The company remains unprofitable with net income of $-3,470,052.00 and a market cap of $24,171,968.35. The timing of multiple insider purchases during a recovery period and well below the 52-week peak merits investor attention, though the company's negative earnings and small market capitalization constrain the overall signal strength.

CEO Gilad Oren bought 250 APRE shares at $2.90; stock now $3.50. Cluster of 4 insiders buying in 14 days as firm unprofitable with -$3.5M net income.

Gilad Oren, President/CEO, purchased 250 shares at $2.90 on 2024-10-15, adding to his 332.6K share position. The purchase occurs amid a cluster in which 3 other insiders also bought within the past 14 days, suggesting synchronized conviction or response to valuation. However, the company reported negative net income of $-3,470,052.00 with a $19.0M market cap, indicating ongoing unprofitability. Oren's cross-ticker buy track record shows an average 90-day return of -38.8% with a 0.00% win rate across 3 prior trades, and his single prior APRE buy (2024-03-13) declined 38.8% over 90 days. The stock is currently down 58.6% from its 52-week high of $8.46, trading below transaction price after a 30-day rally of +13.4%. The multiple insiders' concurrent purchases at depressed levels warrant scrutiny of underlying catalysts, as the pattern conflicts with the insider's historically poor timing on similar buys.

Director Marc Duey buys 190 shares of APRE at $2.58; stock down 58.6% from 52-week high as company posts $-3.5M net loss.

Director Marc Duey purchased 190 shares of Aprea Therapeutics at $2.58 on 2024-10-14, a modest addition to his 210.1K share position. The transaction occurs in a weak fundamental context: the company is unprofitable with $-3.5M net income, and the stock trades 58.6% below its 52-week high. However, this buy coincides with a cluster pattern—3 other insiders also bought within the past 14 days—suggesting coordinated confidence at these depressed price levels. Near-term momentum is mixed: the stock posted a 30-day gain of 13.4% but remains down 12.5% over 90 days. Duey's prior open-market activity shows only 1 prior buy on record, limiting ability to assess a historical timing pattern at this ticker.

CFO John P. Hamill buys 50 APRE shares at $2.46; part of 3-insider cluster; stock down 58.6% from 52-week high, company unprofitable.

Hamill (SrVP/CFO/Prin Fin & Acct Ofcr) purchased 50 shares at $2.46 on 2024-10-11, a modest addition representing +0.3% of his holdings, while the stock trades at $3.50 (down 58.6% from its 52-week high of $8.46). This buy occurred as part of a cluster pattern in which 3 other insiders purchased shares within the past 14 days, suggesting coordinated activity. However, Hamill's cross-ticker track record shows 2 prior open-market buys with an average 90-day return of -38.8% and a 0.00% win rate, while his prior APRE purchase on 2024-03-13 posted a 90-day return of -38.8%. The company reported a net loss of $-3,470,052.00 and remains unprofitable, providing no earnings-based support for the timing. The cluster pattern and insider participation may reflect management's view of valuation, but the CFO's historical execution across multiple transactions has not demonstrated profitable accumulation timing.